XW 014
Alternative Names: XW-014Latest Information Update: 02 Nov 2022
At a glance
- Originator Sciwind Biosciences
- Class Hepatoprotectants; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
- Preclinical Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 11 Oct 2022 Phase-I clinical trials in Type 2 diabetes mellitus in USA (PO)
- 31 Aug 2022 Pharmacokinetics data from a preclinical trial in Metabolic disorder including obesity, type-2 diabetes mellitus and non-alcoholic steatohepatitis (NASH) presented at the International Liver Congress- 2022 (ILC-2022)
- 08 Nov 2021 Preclinical trials in Non-alcoholic steatohepatitis in China (PO)